These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25967074)

  • 1. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
    Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
    Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of CYP2C9 Function in Valproate Therapy.
    Monostory K; Nagy A; Tóth K; Bűdi T; Kiss Á; Déri M; Csukly G
    Curr Neuropharmacol; 2019; 17(1):99-106. PubMed ID: 29119932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
    Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients With Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy.
    Ma B; Yang K; Li X; Su N; Yu T; Zou Y; Xu X; Wang F; Cheng J; Yan Z; Chen T; Zhang L
    Ther Drug Monit; 2024 Aug; 46(4):503-511. PubMed ID: 38287884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
    Smith RL; Haslemo T; Refsum H; Molden E
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.
    Yoon HY; Ahn MH; Yee J; Lee N; Han JM; Gwak HS
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1053-1058. PubMed ID: 32385545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In response: Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children.
    Monostory K; Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Tapodi A; Garami M
    Epilepsia; 2016 Aug; 57(8):1339-40. PubMed ID: 27485380
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
    Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
    Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
    Song C; Li X; Mao P; Song W; Liu L; Zhang Y
    Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
    Sun Y; Yu J; Yuan Q; Wu X; Wu X; Hu J
    Scand J Trauma Resusc Emerg Med; 2017 Aug; 25(1):85. PubMed ID: 28841884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
    Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
    BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate.
    Ugras M; Yakinci C
    Brain Dev; 2006 Oct; 28(9):549-53. PubMed ID: 16842952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy.
    Guo Y; Hu C; He X; Qiu F; Zhao L
    Drug Metab Pharmacokinet; 2012; 27(5):536-42. PubMed ID: 23099353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy.
    Jogamoto T; Yamamoto Y; Fukuda M; Suzuki Y; Imai K; Takahashi Y; Inoue Y; Ohtsuka Y
    Epilepsy Res; 2017 Feb; 130():7-12. PubMed ID: 28081475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
    Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
    Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
    Gunes A; Bilir E; Zengil H; Babaoglu MO; Bozkurt A; Yasar U
    Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):383-6. PubMed ID: 17516991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.